from proactive investorsRegenerative medicine company Regeneus’...

from proactive investors

Regenerative medicine company Regeneus’ (ASX: RGS) clinical study for its HiQCell® stem cell knee osteoarthritis treatment has demonstrated its potential disease modifying effect by slowing cartilage degradation.

Magnetic resonance imaging (MRI) confirmed that participants in the HiQCell® treatment group had slower than expected loss of cartilage at the 6 month post-treatment time point.

In addition, a key cartilage breakdown marker (CTX-II) was found to have stabilised while the inflammation and osteoarthritis biomarker decreased significantly in these participants.

The latter also represents a discovery that the macrophage inhibitory factor (MIF) can be used to accurately measure the anti-inflammatory effects of stem cell treatments.

The study showed that the HiQCell treatment was safe and clinically feasible. It was well tolerated by patients and there were no major safety concerns and no joint infections during the course of the study.

Additionally, the study revealed that HiQCell treatment is effective at reducing pain. Both treatment and placebo groups experienced a large and statistically significant decrease in total pain score from baseline.

http://www.proactiveinvestors.com.au/companies/news/48856/regeneus-clinical-study-confirms-hiqcell-osteoarthritis-treatment-slows-cartilage-degradation-48856.html